Study of the PET-CT with fludeoxyglucose F 18 in oncology: an effective tool for a responsible indication
Keywords:
positron emission tomography with computerized tomography, fludeoxyglucose F 18, oncologyAbstract
Introduction: The study of the positron emission tomography together with computed tomography with fludeoxyglucose F 18 has been revealed as the "gold standard" minimally invasive study for the diagnosis, assessment and follow-up of a wide range of oncological diseases.
Methods: Bibliographic review on the main indications, contraindications, causes of false positives or false negatives and of the most important limitations of the procedure. We broadly explain the preparation and behavior the patient must complete before, during and after the examination for its satisfactory performance are widely explained, the characteristics of the different stages of the acquisition of images, as well as the general dosimetric characteristics that each of them possesses and that must be taken into account to ensure compliance with the principles of radiological protection in the medical practice. We go deeply into details regarding the processing, quantification and interpretation of the images, as well as into the importance for this step of knowing the patient's clinical history, which together with the experience of the multidisciplinary professional group allows to guarantee the adequate evaluation of the changes occurring at the molecular level and that are the basis of the diagnostic efficiency of this technology.
Conclusions: The study of positron emission tomography together with computed tomography with fludeoxyglucose F 18 plays an important role in the management of oncological disease. It is an effective study, but requires special conditions for the preparation of the patient and the development of the study, as well as the integration of a multidisciplinary group of highly-qualified specialists.
Downloads
References
1. Miguel Cantero. Tomografía por emisión de positrones: aspectos técnicos. Radiobiología. 2003 [consultado 30 Ene 2014];3:47-58. Disponible en: http://www.rayos.medicina.uma.es/rmf/radiobiologia/revista/radiobiologia.htm
2. Ronald Boellaard, O'Doherty Mike J, Weber Wolfgang A, Mottaghy Felix M, Markus Lonsdale N, Stroobants Sigrid G, et al. GUIDELINES FDG PET and PET/CT: EANM procedure guidelines for tumour PET imaging: version 1.0 . Eur J Nucl Med Mol Imaging. 2010;37:181-200. DOI 10.1007/s00259-009-1297-4.
3. Fletcher JW, Djulbegovic B, Soares HP, Siegel BA, Lowe VJ, Lyman GH, et al. Recommendations on the use of 18F-FDG PET in oncology. J Nucl Med. 2008;49(3):480-508.
4. IAEA (International Atomic Energy Agency). Appropriate Use of FDG-PET for the Management of Cancer Patients. IAEA Human Health Series. No. 9. International Atomic Energy Agency. Viena: International Atomic Energy Agency; 2010.
5. Nutt R. The history of positron emisión tomography. Mol Imag Biol. 2002;4(1):11-26.
6. Peñuelas I. Radiofármacos PET. Rev Esp Med Nuclear, 20:477-98;2001.
7. Gallagher BM, Fowler JS, Gutterson NI, MacGregor RR, Wan CN, Wolf AP, et al. Metabolic trapping as a principle of radiopharmaceutical design: some factors responsible for the biodistribution of [18F] 2-deoxy-2-fluoro-D-glucose. J Nucl Med. 1978;19:1154-61.
8. IAEA-TECDOC-1603 "The Role of PET/CT in Radiation Treatment Planning for Cancer Patient Treatment". Viena: International Atomic Energy Agency; 2008.
9. Schoder H, Larson SM, Yeung HW. PET/CT in oncology: integration into clinical management of lymphoma, melanoma, and gastrointestinal malignancies. J Nucl Med. 2004;45(Suppl 1):72S-81S.
10. Dondi M, Diana Páez D, Zaknun J, Kashyap R, Bischof Delaloye S, Graham S. A guide for clinicians: PET/CT. AIEA, Medical Imaging for the 21st Century. Viena, Austria; 2010 [consultado 30 Ene 2014]. Disponible en: http://www.iaea.org
11. Martí-Climent JM, García MJ, Serra P, Boan JF, Richter JA. Tomografía por emisión de positrones con un equipo PET/TC. Rev Esp Med Nucl. 2005;24:60-79.
12. Townsend DW, Carney JPJ, Yap JT, Hall HC. PET/CT Today and Tomorrow. J Nucl Med. 2004;45(Suppl):4S-14S.
13. IAEA Human Health Series "Quality Assurance for PET and PET/CT Systems". Viena: International Atomic Energy Agency; 2009.
14. Buchmann I, Henze M, Engelbrecht S, Eisenhut M, Runz A, Schäfer M, et al. Comparison of 68Ga-DOTATOC PET and 111In-DTPAOC (Octreoscan) SPECT in patients with neuroendocrine tumours. Eur J Nucl Med Mol Imaging. 2007;34(10):1617-26.
15. Cristina Nanni, Costantino Erran, Luca Boriani, Lorenzo Fantini, Valentina Ambrosini, Stefano Boschi, et ali. 68Ga-Citrate PET/CT for Evaluating Patients with Infections of the Bone: Preliminary Results. J Nucl Med. 2010;51(12):1932-36.
16. Andrei Iagaru, Erik Mittra, David Dick W, Sanjiv Sam Gambhir. Prospective Evaluation of 99mTc MDP Scintigraphy, 18F NaF PET/CT, and 18F FDG PET/CT for Detection of Skeletal Metastases. Mol Imaging Biol. 2012;14:252-9.
17. Czernin J, Allen-Auerbach M, Schelbert HR. Improvements in cancer staging with PET/CT: literature-based evidence as of September 2006. J Nucl Med. 2007;48(Suppl 1):78S-88S.
18. Fletcher JW, Djulbegovic B, Soares HP, Siegel BA, Lowe VJ, Lyman GH, Coleman RE, Wahl R, Paschold JC, Avril N, Einhorn LH, Suh WW, Samson D, Delbeke D, Gorman M, Shields AF. Recommendations on the use of 18F-FDG PET in oncology. J Nucl Med. 2008;49(3):480-508.
19. K Facey, Bradbury I, Laking G, Payne E. Overview of the clinical effectiveness of positron emission tomography imaging in selected cancers. Health Technology Assessment. 2007;11(44):iii-iv-xi-267.
20. Cleemput I, Dargent G, Poelmans J, Camberlin C, Van den Bruel A, Ramaekers D. HTA positron emission tomography imaging in Belgium. Brussels: Belgian Health Care Knowledge Centre (KCE); 2005.
21. Hillner BE, Siegel BA, Liu D, Shields AF, Gareen IF, Hanna L, et al. Impact of positron emission tomography/computed tomography and positron emission tomography (PET) alone on expected management of patients with cancer: initial results from the National Oncologic PET Registry. J Clin Oncol. 2008;26(13):2155-61.
22. Podoloff DA, Advani RH, Allred C, Benson AB, Brown E, Burstein HJ, Carlson RW, et al. NCCN task force report: positron emission tomography (PET)/computed tomography (CT) scanning in cancer. J Natl Compr Canc Netw. 2007;5(Suppl 1):S1-S22.
23. Thie JA. Understanding the standardized uptake value, its methods, and implications for usage. J Nucl Med. 2004;45:1431-34.
24. Dennis Vriens, Eric Visser P, Lioe-Fee de Geus-Oei, Wim Oyen JG. Methodological considerations in quantification of oncological FDG PET studies. Eur J Nucl Med Mol Imaging. 2010;37:1408-25.
25. Blodgett TM, McCook BM, Federle MP. Positron emission tomography/computed tomography: protocol issues and options. Sem Nucl Med. 2006;36:157-68.
26. Manning K, Tepfer B, Goldklang G, Loyd R, Garimella P, Halkar R. Clinical practice guidelines for the utilization of positron emission tomography/computed tomography imaging in selected oncologic applications: suggestions from a Provider Group. Mol Imaging Biol. 2007;9:324-32.
27. García Garzón JR, Rodríguez A, Cabrera A. Tomografía por emisión de positrones de cuerpo completo (PET/CT) con 18F-fluorodesoxiglucosa. Rev Esp Med Nucl. 2009;28(2):85-89.
28. MUFACE. GUÍA PET-TC Protocolo de Prescripción. Mutualidad General de Funcionarios Civiles del Estado. Madrid; 2011 [citado 30 Ene 2014]. Disponible en: http://www.muface.es
29. Mac Manus M, Nestle U, Rosenzweig KE, Carrio I, Messa C, Belohlavek O, et al. Use of PET and PET/CT for Radiation Therapy Planning: IAEA expert report 2006-2007. Radiotherapy and Oncology. 2009;91:85-94.
30. NCCN. Non-Hodgkin's Lymphomas Clinical Practice Guidelines in Oncology Clinical Practice Guidelines in Oncology TM. Journal of National Comprehensive Cancer Network. 2010;8(3):288-334.
31. Kwee TC, Kwee RM, Nievelstein RA. Imaging in staging of malignant lymphoma: a systematic review. Blood. 2008;111:504-16.
32. Pennant M, Takwoingi Y, Pennant L, Davenport C, Fry-Smith A, Eisinga A, et al. A systematic review of positron emission tomography (PET) and positron emission tomography/computed tomography (PET/CT) for the diagnosis of breast cancer recurrence. Health Technol Assess. 2010;14(50):1-103.
33. IAEA Human Health Series No. 26. Standard Operating Procedures for PET/CT: A Practical Approach for Use in Adult Oncology. Vienna: IAEA; 2013.
34. Boellaard R, O'Doherty MJ, Weber WA, Mottaghy FM, Lonsdale MN, Stroobants SG, et al. GUIDELINES: FDG PET and PET/CT: EANM procedure guidelines for tumour PET imaging: version 1.0. Eur J Nucl Med Mol Imaging. 2010;37:181-200. DOI 10.1007/s00259-009-1297-4.
35. Waxman AD, Herholz K, Lewis DH, Herscovitch P, Minoshima S, Ichise M, et al. Society of Nuclear Medicine Procedure Guideline for FDG PET Brain Imaging. 2009 [cited 2014 Jan 30]. Available from: Procedure Guideline for FDG-PET Brain Imaging v1.0
36. GEMINI™ The world's first and only OPEN PET/CT. Philips Medical. 2004 [consultado 8 Sep 2014]. Disponible en: http://www.medical.philips.com
37. Sopena R, Martí-Bonmatí L. Técnicas de imagen multimodalidad. Todo Hospital. 2009;255:190-6.
38. Medical Imaging PET/CT. Siemens. 2014 [consultado 13 Ago 2014]. Disponible en: http://www.healthcare.siemens.com
39. Discovery PET/CT 710. GE Healthcare. 2017 [consultado 30 Jul 2014]. Disponible en: http://www.gehealthcare.com/
40. Curso de Protección Radiológica en PET/CT. OIEA; 2008 [citado 8 Sep 2014]. Disponible en: https://rpop.iaea.org/RPOP/RPoP/Content/AdditionalResources/Training/1_TrainingMaterial/PETCT.htm
41. IAEA Safety Report Series No. 58. Radiation Protection in newer medical imaging techniques PET/CT. Viena: IAEA; 2008.
42. Calzado A, Geleijns J. Tomografía computarizada. Evolución, principios técnicos y aplicaciones. Rev Fis Med. 2010;11(3):163-80.
43. National Electrical Manufacturers Association (2007). NEMA Standard Publication NU2-2007. Performance measurements of positron emission tomographs. National Electrical Manufacturers Association, Rosslyn; 2007.
44. Surti S, Kuhn A, Werner ME, Perkins AE, Kolthammer J, Karp JS, et al. Performance of Philips Gemini TF PET-CT scanner with special consideration for its time- of-flight imaging capabilities. J Nucl Med. 2007;48(3):471-80.
45. Patton JA, Townsend DW, Hutton BF. Hybrid Imaging Technology: From Dreams and Vision to Clinical Devices. Semin Nucl Med. 2009;39:247-63.
46. Camacho C, Martí JF, Falgás M, Vercher JL. Dosis efectivas asociadas a las exploraciones multimodales habituales en medicina nuclear. Rev Esp Med Nucl. 2011;8:268-78.
47. Brix G, Lechel U, Glatting G, Ziegler SI, Münzing W, Müller SP, et al. Radiation exposure of patients undergoing whole-body dual modality 18F-FDG PET/CT examinations. J Nucl Med. 2005;46:608-13.
48. Report to the General Assembly 2008 with scientific annexes. Sources and effects of ionizing radiation. New York: United Nation Scientific Committee on the Effects of Atomic Radiation; 2010.
Downloads
Published
How to Cite
Issue
Section
License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
Aquellos autores/as que tengan publicaciones con esta revista, aceptan los términos siguientes:
- Los autores/as conservarán sus derechos de autor y garantizarán a la revista el derecho de primera publicación de su obra, el cuál estará simultáneamente sujeto a la Licencia de reconocimiento de Creative Commons que permite a terceros compartir la obra siempre que se indique su autor y su primera publicación esta revista.
- Los autores/as podrán adoptar otros acuerdos de licencia no exclusiva de distribución de la versión de la obra publicada (p. ej.: depositarla en un archivo telemático institucional o publicarla en un volumen monográfico) siempre que se indique la publicación inicial en esta revista.
- Se permite y recomienda a los autores/as difundir su obra a través de Internet (p. ej.: en archivos telemáticos institucionales o en su página web) antes y durante el proceso de envío, lo cual puede producir intercambios interesantes y aumentar las citas de la obra publicada. (Véase El efecto del acceso abierto).
